MX2021011811A - Protacs que degradan el receptor de estrogeno. - Google Patents

Protacs que degradan el receptor de estrogeno.

Info

Publication number
MX2021011811A
MX2021011811A MX2021011811A MX2021011811A MX2021011811A MX 2021011811 A MX2021011811 A MX 2021011811A MX 2021011811 A MX2021011811 A MX 2021011811A MX 2021011811 A MX2021011811 A MX 2021011811A MX 2021011811 A MX2021011811 A MX 2021011811A
Authority
MX
Mexico
Prior art keywords
sup
protacs
compounds
estrogen receptor
receptor degrading
Prior art date
Application number
MX2021011811A
Other languages
English (en)
Inventor
Bin Yang
Thomas George Christopher Hayhow
Bernard Christophe Barlaam
James Stewart Scott
Charlene Fallan
Coura Diene
Johannes Wilhelmus Maria Nissink
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021011811A publication Critical patent/MX2021011811A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La memoria descriptiva se refiere en general a compuestos de Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, donde R1, R2, R3, R4, R6, R7, R8, enlazador, A, G, D y E tienen cualquiera de los significados definidos en la presente. Esta memoria descriptiva también se refiere al uso de tales compuestos y sales farmacéuticamente aceptables de estos en métodos de tratamiento del cuerpo humano o animal, por ejemplo, en la prevención o el tratamiento del cáncer. Esta memoria descriptiva también se refiere a procesos y compuestos intermedios implicados en la preparación de dichos compuestos y a composiciones farmacéuticas que los contienen.
MX2021011811A 2019-03-29 2020-03-27 Protacs que degradan el receptor de estrogeno. MX2021011811A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825924P 2019-03-29 2019-03-29
PCT/EP2020/058702 WO2020201080A1 (en) 2019-03-29 2020-03-27 Estrogen receptor degrading protacs

Publications (1)

Publication Number Publication Date
MX2021011811A true MX2021011811A (es) 2021-10-22

Family

ID=70050126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011811A MX2021011811A (es) 2019-03-29 2020-03-27 Protacs que degradan el receptor de estrogeno.

Country Status (24)

Country Link
US (1) US20220169643A1 (es)
EP (1) EP3947376A1 (es)
JP (1) JP2022526370A (es)
KR (1) KR20210146984A (es)
CN (1) CN113646306A (es)
AR (1) AR118515A1 (es)
AU (1) AU2020252116B2 (es)
BR (1) BR112021019007A2 (es)
CA (1) CA3133763A1 (es)
CL (1) CL2021002489A1 (es)
CO (1) CO2021013927A2 (es)
CR (1) CR20210532A (es)
DO (1) DOP2021000198A (es)
EA (1) EA202192553A1 (es)
EC (1) ECSP21077887A (es)
IL (1) IL286461A (es)
JO (1) JOP20210259A1 (es)
MA (1) MA55495A (es)
MX (1) MX2021011811A (es)
PE (1) PE20220131A1 (es)
SG (1) SG11202110527RA (es)
TW (1) TW202102497A (es)
UY (1) UY38625A (es)
WO (1) WO2020201080A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220348595A1 (en) * 2021-04-09 2022-11-03 Endotarget Inc. Compounds and methods for the targeted degradation of estrogen receptors
TW202321219A (zh) 2021-08-11 2023-06-01 大陸商四川海思科製藥有限公司 雜環衍生物及其組合物和藥學上的應用
WO2023116835A1 (zh) * 2021-12-24 2023-06-29 苏州开拓药业股份有限公司 一种具有酰亚胺骨架的多蛋白降解剂
WO2023212599A2 (en) * 2022-04-26 2023-11-02 Endotarget Inc. Compounds and methods for targeted degradation of estrogen receptors
CN114853751B (zh) * 2022-05-13 2024-01-16 郑州大学第一附属医院 一组吩噻嗪类衍生物及其应用
WO2024015406A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Indole derivatives as estrogen receptor degraders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152394A1 (en) * 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
NO2714752T3 (es) * 2014-05-08 2018-04-21
TW201815789A (zh) * 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
SI3660004T1 (sl) 2016-10-11 2023-08-31 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
AU2017366693B2 (en) 2016-12-01 2021-04-01 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
MX2019008934A (es) * 2017-01-26 2019-11-05 Arvinas Operations Inc Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.

Also Published As

Publication number Publication date
EA202192553A1 (ru) 2022-02-21
CN113646306A (zh) 2021-11-12
WO2020201080A1 (en) 2020-10-08
CA3133763A1 (en) 2020-10-08
EP3947376A1 (en) 2022-02-09
UY38625A (es) 2020-10-30
TW202102497A (zh) 2021-01-16
AU2020252116A1 (en) 2021-11-11
ECSP21077887A (es) 2021-11-30
KR20210146984A (ko) 2021-12-06
CL2021002489A1 (es) 2022-06-03
CR20210532A (es) 2022-02-10
JOP20210259A1 (ar) 2023-01-30
SG11202110527RA (en) 2021-10-28
MA55495A (fr) 2022-02-09
IL286461A (en) 2021-10-31
JP2022526370A (ja) 2022-05-24
DOP2021000198A (es) 2021-10-31
BR112021019007A2 (pt) 2021-11-30
AR118515A1 (es) 2021-10-20
PE20220131A1 (es) 2022-01-27
CO2021013927A2 (es) 2021-10-29
AU2020252116B2 (en) 2023-04-27
US20220169643A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
CR20230185A (es) Compuestos y su uso en el tratamiento del cáncer
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CR20220105A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
ZA202006071B (en) Antiproliferation compounds and uses thereof
KR20150136074A (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2021012105A (es) Compuestos de pirrol.
JOP20190209A1 (ar) مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos
MX2021006095A (es) Pirazoles como moduladores de hemoglobina.
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
JOP20190278A1 (ar) مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
ZA202104617B (en) Pharmaceutical compound, the method of its making and use as medicinal agent
CR20210086A (es) Formulaciones de dendrímeros
WO2022204344A3 (en) Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents